Articles

The mitomycin-containing reverse thermal gel UGN-101 (Jelmyto) produced durable responses in patients with low-grade upper tract urothelial carcinoma.

UGN-101 shows long-term recurrence-free survival benefit in low-grade UTUC

The 12-month recurrence-free survival rate was 42.9% for those who received BCG alone compared with 44.4% for those who received the combination.

Combination Panvac-BCG does not significantly improve outcomes in non–muscle invasive bladder cancer

Benjamin P. Saylor is associate editor of Urology Times, an Advanstar Communications publication.

“At 365 days, the rate of return procedures was lowest for the UroLift. The rate of return procedures was higher after Rezum versus UroLift,” says Steven A. Kaplan, MD.

Real-world data point to low complication rate for prostatic urethral lift

Videos

“We need to treat our patients with stones, both medically and surgically,” says Glenn M. Preminger, MD.

Dr. Preminger on future advancements related to stone prevention

Data from the phase 1b ABC Trial showed that adding avelumab to BCG induction therapy may be safe and well tolerated in patients with BCG-unresponsive non–muscle invasive bladder cancer.



Avelumab/BCG induction appears safe, tolerable in BCG-unresponsive NMIBC

“Asian men had the lowest rates of ED treatments compared to Caucasian men, regardless of modality of treatment,” says Tony Chen, MD.

Asian and Hispanic men are less likely to receive treatment for erectile dysfunction

"The device is noninvasive and used in awake subjects. This case demonstrates that even chronic fragments can be successfully cleared, sometimes within hours of the procedure, even if they have not previously cleared for months,” said Mathew Sorensen, MD.

Ultrasonic propulsion device clears chronic residual stone fragments

“This is the beginning of an exploration and an identification,” says Steven A. Kaplan, MD.

Dr. Kaplan discusses patient selection for BPH treatments

Interim results from the ROBUST III trial were presented at the 2021 AUA Annual Meeting. 

Dr. Elliot on ROBUST III trial of Optilume drug-coated balloon for anterior urethral strictures

Long-term findings from 2 cohorts of a phase 3 study showed sustained efficacy with the novel intravesical gene therapy in patients with BCG-unresponsive non–muscle invasive bladder cancer. 